Pyxis Oncology Files Definitive Proxy Statement

TL;DR

Pyxis Oncology filed its proxy statement for a shareholder meeting. No fee required.

AI Summary

Pyxis Oncology, Inc. filed a definitive proxy statement (DEF 14A) on September 25, 2024, related to a special meeting. The filing indicates no fee was required for this filing, suggesting it's a standard procedural document rather than a major event requiring a fee.

Why It Matters

This filing is a routine proxy statement, indicating the company is preparing for a shareholder meeting to vote on corporate matters.

Risk Assessment

Risk Level: low — This is a standard procedural filing for a proxy statement, not indicating any immediate financial or operational risk.

Key Numbers

• No fee required — Filing Fee (Indicates a standard proxy filing, not a transaction requiring a fee.)

Key Players & Entities

• Pyxis Oncology, Inc. (company) — Registrant
• 0000950170-24-109337 (filing_id) — Accession Number
• 20240925 (date) — Filing Date

FAQ

Key Financial Figures

• $0.001 — 5 shares of our common stock, par value $0.001 per share, were outstanding. Only holde
• $1,000,000, m — y non-employee director will not exceed $1,000,000, multiplied by 1.5x with respect to the fi
• $3.69 — on the Nasdaq Global Select Market was $3.69 per share. 5 Plan Administration. T

Filing Documents

• 2024_pyxs-special_mtg_14.htm (DEF 14A) — 805KB
• img26991058_0.jpg (GRAPHIC) — 29KB
• img26991058_1.jpg (GRAPHIC) — 17KB
• img26991058_2.jpg (GRAPHIC) — 40KB
• img26991058_3.jpg (GRAPHIC) — 1381KB
• img26991058_4.jpg (GRAPHIC) — 185KB
• 0000950170-24-109337.txt ( ) — 3081KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION ​ ​ 13

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 19 ADDITIONAL INFORMATION ​ ​ 22 APPENDIX A-1 23 APPENDIX A-2 24   PYXIS ONCOLOGY, INC.   321 Harrison Avenue Boston, Massachusetts 02118   SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON OCTOBER 23, 2024   PROXY STATEMENT   GENERAL INFORMATION This proxy statement is furnished to stockholders of Pyxis Oncology, Inc. (“we,” “us,” “our,” the “Company” or “Pyxis Oncology”), a Delaware corporation, in connection with the solicitation of proxies by our board of directors (the “Board”) for use at our Special Meeting of stockholders to be held on October 23, 2024 (the “Special Meeting”), and at any adjournment or postponement thereof. The Special Meeting will be held at 10:00 a.m. Eastern Standard Time in a virtual meeting format. In order to attend the Special Meeting, you must register at www.proxydocs.com/PYXS . Upon completing your registration, you will receive further instructions via email, including a unique link that will allow you access to the Special Meeting and to vote and submit questions during the Special Meeting. This proxy statement and the accompanying proxy card are first being made available to stockholders on or about September 25, 2024. Please note that references to our website herein do not constitute incorporation by reference of the information contained at or available through our website. Why am I receiving these materials? We are distributing our proxy materials because our Board is soliciting your proxy to vote at the Special Meeting. This proxy statement summarizes the information you need to vote at the Special Meeting. You do not need to attend the Special Meeting to vote your shares. We encourage you to vote promptly to ensure your vote is represented at the Special Meeting, regardles